NCT00551239View on ClinicalTrials.gov

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2007

Conditions

LeukemiaLymphoma

Interventions

BIOLOGICAL

rituximab

Given IV

DRUG

fludarabine phosphate

Given IV

DRUG

pixantrone dimaleate

Given IV

Trial Locations (1)

98119

Cell Therapeutics, Incorporated, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CTI BioPharma

INDUSTRY